Brigham XPRIZE and NMN: The Connection Traces to a Screening Patent
Eternal Search links the Brigham Boston XPRIZE Healthspan team to NMN through an aging-agent screening patent from Centre for Translational Stem Cell Biology; the same project maps to eight other compounds, placing NMN in a broader screening context.
Shalender Bhasin and JoAnn Manson lead the Brigham-Boston XPRIZE Healthspan team out of Mass General Brigham and Harvard. In 2025 they reached the Top 40 semifinalists in XPRIZE Healthspan, a seven-year, $101M competition aimed at extending healthy lifespan, and received $250,000 in Milestone 1 funding. Their therapeutic candidate remains unnamed.
In Eternal Search, this project links to NMN (nicotinamide mononucleotide, a precursor of NAD, a coenzyme in cellular energy metabolism). The link traces to a patent from Centre for Translational Stem Cell Biology: "Composition and methods of aging-related agent screening and target analysis" (WO2024061369A1), which describes an aging-agent screening method where cells were treated with NMN at 1 μM and 10 μM. Whether this patent has any institutional tie to the Brigham team, the data does not say.
The same project also links to rapamycin, metformin, fisetin, resveratrol, quercetin, taurine, acarbose, and CoQ10. What NMN did to cells at those concentrations is not in the available evidence. Overall project rating: 41.2; pilot stage, no clinical results yet.
The edge between a high-profile, undisclosed-therapeutic competition project and a well-known NAD precursor is easy to misread as a drug reveal; surfacing the actual evidence document (a third-party screening patent from a different institution) and the full nine-compound neighborhood corrects that before the connection circulates as speculation.